Quarterly report pursuant to Section 13 or 15(d)

Discontinued Operations (Tables)

v3.7.0.1
Discontinued Operations (Tables)
3 Months Ended
Mar. 31, 2017
Discontinued Operations Tables  
Discontinued Operations
   

March 31,

2017

    December 31, 2016  
Accounts and other receivables   $     $ 1,598,994  
Inventory, net           1,374,618  
Prepaid expenses           170,635  
Assets associated with discontinued operations, current           3,144,247  
Property and equipment, net of accumulated depreciation           70,973  
Patents and trademarks, net of accumulated amortization           34,282  
Assets associated with discontinued operations, noncurrent           105,255  
Total assets associated with discontinued operations   $     $ 3,249,502  
                 
Accounts payable   $ 152,108     $ 1,957,938  
Accrued liabilities     3,402,212       607,659  
Deferred revenue           2,300,000  
Liabilities associated with discontinued operations, current   $ 3,554,320     $ 4,865,597  

 

    Three Months Ended March 31,  
    2017     2016  
Revenue:            
Lymphoseek sales revenue   $ 2,917,213     $ 3,773,880  
Grant and other revenue           190  
Total revenue     2,917,213       3,774,070  
Cost of goods sold     364,192       533,440  
Gross profit     2,553,021       3,240,630  
Operating expenses:                
Research and development     283,533       587,249  
Selling, general and administrative     820,203       1,463,534  
Total operating expenses     1,103,736       2,050,783  
Income from discontinued operations     1,449,285       1,189,847  
Interest expense     (1,718,506 )     (2,194,280 )
Loss before income taxes     (269,221 )     (1,004,433 )
Benefit from income taxes     13,360        
Loss from discontinued operations   $ (255,861 )   $ (1,004,433 )